“…more elevated in CHC users compared to non-users, while interestingly no increased risk was found for POP users [12,13]. Surprisingly, although progestins have a lower cardiovascular risk compared to CHC, only a few studies have evaluated these compounds in this high-risk population of patients with MO [21][22][23][24] and the use of progestins has not been consistent over time, probably due to the fact that these compounds cause more adverse effects (such as weight gain, mastalgia and irregular menstrual bleeding) than CHCs and that they might be less tolerated by the patients [25]. Over the last two years, renewed interest has been focused on the use of progestins (desogestrel-only pill) in migrainous women.…”